The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1748
February 16, 2026
View Complete Issue         Table of Contents 2019 
A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension
February 16, 2026 (Issue: 1748)
Yutrepia (Liquidia), a dry powder inhaler formulation of the prostacyclin analog treprostinil, has been approved by the FDA to improve exercise ability in adults with pulmonary arterial hypertension (PAH; WHO Group 1) or pulmonary hypertension...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension
Article code: 1748b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.